This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A study published in the journal Nature Communications has identified a new pathway that human immunodeficiency virus (HIV) uses to enter the nucleus of a healthy cell, where it can then replicate and go on to invade other cells. But how the viruses get past the protective membrane is not well understood and is the subject of much debate.
A study published in the journal Nature Communications has identified a new pathway that human immunodeficiency virus (HIV) uses to enter the nucleus of a healthy cell, where it can then replicate and go on to invade other cells. But how the viruses get past the protective membrane is not well understood and is the subject of much debate.
The traditional model of drugdevelopment and healthcare delivery is undergoing a seismic shift, with patient engagement emerging as a critical factor in achieving better health outcomes and driving innovation. This change is further driven by major regulatory bodies emphasizing Patient-Focused DrugDevelopment (PFDD).
Teams and Zoom became the backbone of communication and firms embraced new ways of working. However, if considered early in the drugdevelopment plan, compliance is by no means insurmountable and would be offset by the benefits of digital healthcare tools for patient engagement. About the interviewees.
Delivering value for patients doesn’t start and end in our R&D labs; actions can be implemented across all stages of the drugdevelopment lifecycle to encourage and embrace a pro-innovation environment. The role of innovation in value-based healthcare.
But what are the key potential changes and how could they impact drugdevelopers and manufacturers? He noted that within the proposals, there is likely to be a differentiation in incentives for drugdevelopment in the orphan and unmet medical need areas. Key areas of potential legislative change. Future outlook.
MACC Commissioner United States Food and Drug Administration 5 630 Fishers Lane, Rm. MACC Commissioner United States Food and Drug Administration 5 630 Fishers Lane, Rm. The NHC was a strong supporter of the inclusion of these guidances in the Prescription Drug User Fee Act (PDUFA) VI agreement. Califf M.D., Califf M.D.,
The guidance describes elements that would be required of VCS bodies for recognition of standards they adopt: openness (with meaningful opportunities to participate), balance (broad range of stakeholders), due process, an appeals process, and consensus.
As formulators, we are often able to directly impact the amount of drug absorbed through formulation optimization and improve exposure. However, the chances of improving the exposure profile of a drug that is highly cleared by formulation modification are limited. Please check your email to download the Whitepaper.
The demand for injectable drugs is rising. According to the GlobalData report Contract Injectable Packaging Trends in the Bio/Pharma Industry , more than half (55%) of FDA drug approvals in 2021 were accounted for by injectables. Several drugdevelopment trends are driving injectables demand.
Forward-thinking suppliers, including packaging component providers, are also looking at how they can improve their processes through digital technologies. Tom Lenaerts is head of global process engineering for Datwyler, a leading supplier of parenteral packaging components such as stoppers and plungers. Free Whitepaper. By Datwyler.
We source as much of the materials as we possibly can locally, even packaging,” he notes. When we need new packaging, it is really simple to get and it is quick. To learn more about the development and partnership opportunities for businesses within Scotland’s health sector, download the document on this page. Free Whitepaper.
A vitally important assay used across various stages of drugdevelopment and manufacturing, container closure integrity testing (CCIT) involves evaluating packaging systems to determine their ability to protect the stability and sterility of pharmaceutical products. The evolution of CCIT.
Navigating the complex landscape of drugdevelopment and manufacturing can be a daunting task. Enter the Contract Development and Manufacturing Organization (CDMO) a lifeline for many startups looking to bring their innovative therapies to market. To truly succeed, you need to build a strong, collaborative partnership.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content